Search

Your search keyword '"Mulinacci G"' showing total 8 results
Start Over Author "Mulinacci G" Publisher elsevier bv
8 results on '"Mulinacci G"'

3. A quantitative MRCP-derived score for medium-term outcome prediction in primary sclerosing cholangitis

Author

Cristoferi, L., primary, Porta, M., additional, Bernasconi, D.P., additional, Leonardi, F., additional, Gerussi, A., additional, Mulinacci, G., additional, Palermo, A., additional, Gallo, C., additional, Scaravaglio, M., additional, Stucchi, E., additional, Maino, C., additional, Ippolito, D., additional, D'Amato, D., additional, Ferreira, C., additional, Nardi, A., additional, Banerjee, R., additional, Valsecchi, M.G., additional, Antolini, L., additional, Corso, R., additional, Sironi, S., additional, Fagiuoli, S., additional, Invernizzi, P., additional, and Carbone, M., additional

Published
2022
Full Text
View/download PDF

4. Takayasu arteritis and primary sclerosing cholangitis: A casual association or different phenotypes of the same disease?

Author

Mulinacci, G, Palermo, A, Cristoferi, L, Invernizzi, P, Carbone, M, Mulinacci G., Palermo A., Cristoferi L., Invernizzi P., Carbone M., Mulinacci, G, Palermo, A, Cristoferi, L, Invernizzi, P, Carbone, M, Mulinacci G., Palermo A., Cristoferi L., Invernizzi P., and Carbone M.

Abstract

Takayasu arteritis and primary sclerosing cholangitis are two rare disorders. The pathogenesis of Takayasu arteritis involves immune-mediated mechanisms, and corticosteroids represent the mainstay for treatment. Conversely, the aetiology of primary sclerosing cholangitis remains elusive, even if dysimmunity seems to be one of the contributors to bile duct damage. Despite this, immunosuppressants do not alter disease course. In this paper we describe the association of these two rare disorders, with an unexpected normalization of cholestatic enzymes following steroid treatment. This might hint a novel subtype of sclerosing cholangitis with a prevalent immunebackground, or a local manifestation of Takayasu arteritis.

Published
2021

5. PC.01.8 RADIOMICS-BASED MODEL FOR OUTCOME PREDICTION IN PRIMARY SCLEROSING CHOLANGITIS

Author

Cristoferi, L., primary, Porta, M., additional, Bernasconi, D.P., additional, Leonardi, F., additional, Mulinacci, G., additional, Palermo, A., additional, Gerussi, A., additional, Scaravaglio, M., additional, Gallo, C., additional, D’Amato, D., additional, Maino, C., additional, Ippolito, D., additional, Ferreira, C., additional, Mavar, M., additional, Rajarshi, B., additional, Antolini, L., additional, Valsecchi, M.G., additional, Fagiuoli, S., additional, Invernizzi, P., additional, and Carbone, M., additional

Published
2022
Full Text
View/download PDF

6. Radiomics-based model for outcome prediction in primary sclerosing cholangitis

Author

Cristoferi, L., primary, Porta, M., additional, Bernasconi, D.P., additional, Leonardi, F., additional, Mulinacci, G., additional, Palermo, A., additional, Gerussi, A., additional, Gallo, C., additional, Scaravaglio, M., additional, Stucchi, E., additional, Maino, C., additional, Ippolito, D., additional, D'Amato, D., additional, Ferreira, C., additional, Mavar, M., additional, Banerjee, R., additional, Antolini, L., additional, Valsecchi, M.G., additional, Fagiuoli, S., additional, Invernizzi, P., additional, and Carbone, M., additional

Published
2022
Full Text
View/download PDF

7. Predictors of Serious Adverse Event and Non-response in Cirrhotic Patients With Primary Biliary Cholangitis under Obeticholic Acid

Author

De Vincentis, A., primary, D'Amato, D., additional, Cristoferi, L., additional, Gerussi, A., additional, Malinverno, F., additional, Lleo, A., additional, Colapietro, F., additional, Marra, F., additional, Galli, A., additional, Fiorini, C., additional, Coco, B., additional, Brunetto, M., additional, Niro, G.A., additional, Cotugno, R., additional, Saitta, C., additional, Cozzolongo, R., additional, Losito, F., additional, Giannini, E.G., additional, Labanca, S., additional, Marzioni, M., additional, Marconi, G., additional, Morgando, A., additional, Pellicano, R., additional, Vanni, E., additional, Cazzagon, N., additional, Floreani, A., additional, Chessa, L., additional, Morelli, O., additional, Muratori, L., additional, Pellicelli, A., additional, Pompili, M., additional, Ponziani, F., additional, Rosina, F., additional, Russello, M., additional, Cannavò, M., additional, Simone, L., additional, Storato, S., additional, Viganò, M., additional, Abenavoli, L., additional, D'Antò, M., additional, De Gasperi, E., additional, Distefano, M., additional, Scifo, G., additional, Zolfino, T., additional, Calvaruso, V., additional, Cuccorese, G., additional, Pace Palitti, V., additional, Sacco, R., additional, Bertino, G., additional, Frazzetto, E., additional, Alvaro, D., additional, Mulinacci, G., additional, Palermo, A., additional, Galati, G., additional, Ronca, V., additional, Zuin, M., additional, Claar, E., additional, Izzi, A., additional, Picardi, A., additional, Invernizzi, P., additional, Vespasiani-Gentilucci, U., additional, and Carbone, M., additional

Published
2022
Full Text
View/download PDF

8. A quantitative MRCP-derived score for medium-term outcome prediction in primary sclerosing cholangitis

Author

Laura Cristoferi, Marco Porta, Davide Paolo Bernasconi, Filippo Leonardi, Alessio Gerussi, Giacomo Mulinacci, Andrea Palermo, Camilla Gallo, Miki Scaravaglio, Eliana Stucchi, Cesare Maino, Davide Ippolito, Daphne D'Amato, Carlos Ferreira, Alessandra Nardi, Rajarshi Banerjee, Maria Grazia Valsecchi, Laura Antolini, Rocco Corso, Sandro Sironi, Stefano Fagiuoli, Pietro Invernizzi, Marco Carbone, Cristoferi, L, Porta, M, Bernasconi, D, Leonardi, F, Gerussi, A, Mulinacci, G, Palermo, A, Gallo, C, Scaravaglio, M, Stucchi, E, Maino, C, Ippolito, D, D'Amato, D, Ferreira, C, Nardi, A, Banerjee, R, Valsecchi, M, Antolini, L, Corso, R, Sironi, S, Fagiuoli, S, Invernizzi, P, and Carbone, M

Subjects
sclerosing cholangitis, Artificial intelligence, Hepatology, Prognostic score, Gastroenterology, Primary sclerosing cholangiti, MRCP
Abstract

Background: Magnetic resonance cholangiopancreatography (MRCP) is the gold standard for diagnosis of patients with primary sclerosing cholangitis (PSC). The semi-quantitative MRCP-derived Anali scores proposed for risk stratification, have poor-to-moderate inter-reader agreement. Aims: To evaluate the prognostic performance of quantitative MRCP metrics in PSC. Methods: This is a retrospective study of PSC patients undergoing MRCP. Images were processed using MRCP+ software (Perspectum Ltd, Oxford) that provides quantitative biliary features, semi-automatically extracted by artificial intelligence-driven analysis of MRCP-3D images. The prognostic value of biliary features has been assessed for all hepato-biliary complications. Results: 87 PSC patients have been included in the analysis. Median follow-up from MRCP to event/censoring of 30.9 months (Q1-Q3=13.6–46.6). An adverse outcome occurred in 27 (31.0%) patients. The number of biliary strictures (HR=1.05 per unit, 95%CI 1.02–1.08, p < 0.0001), spleen length (HR=1.16 per cm, 95%CI 1.01–1.34, p = 0.039), adjusted for height, age at MRCP, and time from diagnosis to MRCP predicted higher risk of hepatobiliary complications. These were incorporated into a the quantitative MRCP-derived PSC (qMRCP-PSC) score (C-statistic=0.80). After 3-fold cross-validation, qMRCP-PSC outperformed the Anali score in our cohort (C-statistic of 0.78 vs 0.64) and enabled the discrimination of survival of PSC patients (log-rank p < 0.0001). Conclusions: The qMRCP-PSC score identified patients at higher risk of hepatobiliary complications and outperformed the available radiological scores. It represents a novel quantitative biomarker for disease monitoring and a potential surrogate endpoint for clinical trials.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results